Niagen Bioscience (NAGE) Return on Capital Employed (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Return on Capital Employed data on file, last reported at 14.94% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 14.94%, down 957.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 14.94% (down 957.0% YoY), and the FY2025 annual result was 24.14%, up 645.0% from the prior year.
• Return on Capital Employed declined to 14.94% in Q1 2026 per NAGE's latest filing, from 19.77% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 26.77% in Q3 2025 and troughed at 88.23% in Q2 2022.
• A 5-year average of 16.75% and a median of 12.44% in 2024 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed tumbled 1515 bps in 2022, then jumped 6268 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 58.23% in 2022, then soared by 71 bps to 16.66% in 2023, then soared by 204 bps to 17.38% in 2024, then increased by 14 bps to 19.77% in 2025, then retreated by 24 bps to 14.94% in 2026.
• Business Quant data shows NAGE's Return on Capital Employed at 14.94% in Q1 2026, 19.77% in Q4 2025, and 26.77% in Q3 2025.